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Objective. To revise the south african Guideline for the Management 
of chronic Obstructive pulmonary Disease (cOpD) based on 
emerging research that has informed updated recommendations.
Key points.
1.    smoking is the major cause of cOpD, but exposure to biomass 
fuels and tuberculosis are important additional factors.
2.    spirometry is essential for the diagnosis and staging of cOpD.
3.    cOpD is either undiagnosed or diagnosed too late, so limiting 
the benefit of therapeutic interventions; performing spirometry 
in at-risk individuals will help to establish an early diagnosis.
4.    Oral corticosteroids are no longer recommended for maintenance 
treatment of cOpD.
5.    a therapeutic trial of oral corticosteroids to distinguish 
corticosteroid responders from non-responders is no longer 
recommended.
6.    primary and secondary prevention are the most cost-effective 
strategies in cOpD. smoking cessation as well as avoidance 
of other forms of pollution can prevent disease in susceptible 
individuals and ameliorate progression. Bronchodilators are 
the mainstay of pharmacotherapy, relieving dyspnoea and 
improving quality of life.
7.    inhaled corticosteroids are recommended in patients with 
frequent exacerbations and have a synergistic effect with 
bronchodilators in improving lung function, quality of life and 
exacerbation frequency.
8.    acute exacerbations of cOpD significantly affect morbidity, 
health care units and mortality.
9.    antibiotics are only indicated for purulent exacerbations of 
chronic bronchitis.
10.    cOpD patients should be encouraged to engage in an active 
lifestyle and participate in rehabilitation programmes.
Options. Treatment recommendations are based on the following: 
annual updates of the Global Obstructive lung Disease  (GOlD), 
initiative, that provide an evidence-based comprehensive review of 
management; independent evaluation of the level of evidence in 
support of some of the new treatment trends; and consideration 
of factors that influence cOpD management in south africa, 
including lung co-morbidity and drug availability and cost.
Outcome. Holistic management utilising pharmacological and non-
pharmacological options are put in perspective.
Evidence. working groups of clinicians and clinical researchers 
following detailed literature review, particularly of studies performed 
in south africa, and the GOlD guidelines.
Benefits, harms and costs. The guideline pays particular attention 
to cost-effectiveness in south africa, and promotes the initial use 
of less costly options. it promotes smoking cessation and selection 
of treatment based on objective evidence of benefit. it also rejects 
a nihilistic or punitive approach, even in those who are unable to 
break the smoking addiction.
Recommendations. These include primary and secondary prevention; 
early diagnosis, staging of severity, use of bronchodilators and other 
forms of treatment, rehabilitation, and treatment of complications. 
advice is provided on the management of acute exacerbations and 
the approach to air travel, prescribing long-term oxygen and lung 
surgery including lung volume reduction surgery.
Validation. The cOpD working Group comprised experienced 
pulmonologists representing all university departments in south 
africa and some from private practice, and general practitioners. 
Most contributed to the development of the previous version of the 
south african guideline.
Guideline sponsor. The meeting of the working Group of the 
south african Thoracic society was sponsored by an unrestricted 
educational grant from Boehringer ingelheim and Glaxo-smith-
kline.
S Afr Med J 2011; 101: 61-73.
Guideline for the management of chronic obstructive 
pulmonary disease – 2011 update
M s Abdool-Gaffar, A Ambaram, G M Ainslie, C T Bolliger, C feldman, l Geffen, E M Irusen, J Joubert, u G lalloo, T T Mabaso, K 
Nyamande, J O’Brien, W Otto, R Raine, G Richards, C smith, D stickells, A venter, s visser, M Wong
Doctor in private practice, Cape Town 
l Geffen, MB chB
Division of Pulmonology, Department of Medicine, Stellenbosch University 
J Joubert, Fcp (sa), MD
Department of Pulmonology and Critical Care, Nelson R Mandela School of Medicine, 
University of KwaZulu-Nata,l and Inkosi Albert Luthuli Hospital, Durban 
u G lalloo, MB chB, MD, Fcp (sa), DOH, Fccp, Frcp
Doctor in private practice, Durban 
T T Mabaso, MB chB
Department of Pulmonology and Critical Care, Nelson R Mandela School of Medicine, 
University of KwaZulu-Natal 
K Nyamande, Fcp MD
Pulmonologist in private practice, Cape Town 
J O’Brien, MB chB, Fcp (sa)
Department of Internal Medicine, University of the Free State, Bloemfontein 
W Otto, MB chB, MMed (int)
GuIDElINEs
January 2011, vol. 101, no. 1  sAMJ64
chronic obstructive pulmonary disease (cOpD) is a significant cause 
of death and disability in both developed and developing countries. 
it is increasing in frequency and demands increasing utilisation of 
healthcare resources. cigarette smoking remains the major cause 
of cOpD but, in developing countries, biomass fuel smoke and 
tuberculosis are important additional causes.
This revised guideline is based on the following premises: (i) cOpD 
is an inflammatory disorder, and (ii) while cOpD is associated with 
partial reversibility of the airflow limitation using simple spirometry, 
modern treatment results in significant symptomatic improvement in 
quality of life (QOl) and morbidity.
1.  Definition
cOpD is a disease state resulting from an abnormal inflammatory 
response of the lungs to irritant particles and gases, with resultant 
progressive airflow limitation that is partially reversible. it is associated 
with lung hyperinflation and systemic effects. The pathological 
correlates are chronic bronchitis and emphysema.1,2
2.  Epidemiology of COPD
cOpD is one of the leading causes of morbidity and mortality in the 
world. it is estimated that there are currently over 280 million cases 
in the world, a significant proportion of whom are undiagnosed. The 
prevalence of cOpD is projected to rise owing to increased exposure 
to risk factors and population ageing.3,4 a recent meta-analysis of 26 
cOpD studies in 28 countries reported a pooled prevalence estimate 
of 8.9%.5
The Burden of Obstructive lung Disease (BOlD) study6 that 
investigated the prevalence of cOpD in various countries showed 
that cOpD prevalence varied considerably in different countries, 
with a range of 6 - 19% for stage ≥2 cOpD (clinically significant 
disease) and 12 - 26% for stage ≥1 cOpD. south africa had the 
highest prevalence of stage ≥2 cOpD (19% overall, 22% male and 
17% female), which may be greater than the general south african 
prevalence because of the higher incidence of smoking, occupational 
dust exposure, indoor pollution and prior tuberculosis in the area 
studied. unlike other chronic diseases, cOpD mortality for both men 
and women is increasing. The Global Burden of Disease study has 
projected that cOpD, which was ranked 6th as the cause of death in 
1990, will become the third leading cause of death by 2020.7,8
3.  Risk factors
The prevalence of cOpD is generally directly related to the prevalence 
of tobacco smoking, but other factors are also involved. The risk for 
cOpD results from a host-environment interaction; the factors are 
shown in Table i.
3.1  Host
Genetic
The genetic risk factor that is best documented is the hereditary 
deficiency of alpha-1 protease inhibitor.9 There is also an increased risk 
of airflow obstruction in the smoking siblings of patients with severe 
cOpD, suggesting that other genetic factors are involved.10 Genes 
associated with cOpD susceptibility in smokers are increasingly 
being identified.11
Age
cOpD prevalence increases with age, but this probably relates more 
to the increased cumulative burden of exposure to risk factors 
(smoking, pollution, infection, etc.) than age per se.12,13
Gender
cOpD prevalence and mortality is greater among men than women, 
and reflects previous smoking patterns. The prevalence is now 
equalising in developed countries. women may be more susceptible 
than men to the effects of tobacco smoke.14
lung growth and development
poor lung growth owing to problems in utero and exposure during 
childhood is associated with airflow obstruction in adulthood.15,16
3.2  Environment
Inhalational exposure
Tobacco smoke
cOpD is more common in smokers and ex-smokers than in non-
smokers. cigarette smokers have more respiratory symptoms, lung 
function abnormalities, decline in Fev1, and cOpD mortality than 
non-smokers. The starting age, total pack-years smoked and current 
smoking status are predictive of cOpD morbidity and mortality.17 
The annual decline of Fev1 in smokers varies from 55 - 100 ml/
year v. about 30 ml/yr in non-smokers.18 However, not all smokers 
develop clinically significant cOpD so genetic factors must modify 
risk.19  The oft-quoted figure of only 15% of smokers developing 
cOpD is probably an under-estimate.20 pipe and cigar smokers have 
greater cOpD morbidity and mortality rates than non-smokers, 
although their rates are lower than those for cigarette smokers. 
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Table I. Risk factors for the development of COPD
A.  Host
1.  Genes (e.g. alpha-1 protease inhibitor deficiency)
2.  age
3.  Gender
4.  lung growth and development
B.  Environment
inhalational exposure:
1.  tobacco smoke
2.  cannabis
3.  occupational dusts and chemicals
4.  indoor air pollution (heating/cooking with biomass fuels)
5.  outdoor air pollution
C. Infections (e.g. childhood respiratory infection, TB, Hiv)
D. socio-economic status
E. Nutrition
GuIDElINEs
65January 2011, vol. 101, no. 1  sAMJ
passive or environmental tobacco smoke (eTs) may also contribute 
to cOpD.21,22 smoking during pregnancy may predispose to cOpD 
by decreasing lung growth and development in the fetus.23
Cannabis
smoking cannabis is associated with a dose-related airflow 
obstruction.24  One cannabis joint is equivalent to 2.5 - 5 tobacco 
cigarettes.
Occupational dusts and chemicals
Occupational dust and chemical exposure is an independent cause of 
cOpD.25 The large population-based nHanes iii (national Health 
and nutrition examination survey) utilising spirometry in almost 10 
000 adults estimated that the fraction of cOpD attributable to work 
was 19% overall and 31% among never-smokers.26
Indoor air pollution
The burning of biomass and fossil fuels (wood, animal dung, crop 
residues and coal) in open fires or poorly-functioning stoves in 
poorly-ventilated spaces leads to very high levels of indoor air 
pollution. almost half the world’s population, and 90% of rural 
families (including >20 million in south africa), use biomass and 
coal as their main source of energy for cooking and heating.27,28 
several case-control and community-based studies have shown that 
this is associated with an increased risk for cOpD in developing 
countries, especially among non-smoking women.29-31 it is estimated 
that 2 million women and children die globally in consequence each 
year.7
Outdoor air pollution
air pollution, mainly from motor vehicle emissions in cities and 
biomass smoke (from bush and forest fires), is associated with loss 
of lung function.32-34
3.3  Infections
childhood respiratory infections are associated with reduced lung 
function and increased respiratory symptoms in adulthood.35 several 
studies have shown that previous pulmonary tuberculosis may lead 
to cOpD.36-39 Hiv infection has been shown to accelerate the onset 
of smoking-related emphysema.40 in addition, viral and bacterial 
infections may contribute to the pathogenesis and progression of 
cOpD.41
3.4  socioeconomic status
There is a higher prevalence of cOpD among the lower socioeconomic 
strata,42 but this probably reflects increased exposure to smoking, 
indoor and outdoor air pollution, susceptibility to infections and 
poor nutrition.
3.5  Nutrition
The role of nutrition as an independent risk factor for the development 
of cOpD is unclear. severe malnutrition has been associated with 
emphysema.43
4.  Aim of this guideline
The purpose of this guideline is to improve the care of patients with 
cOpD at all levels of the health system in south africa and to provide 
information that will assist in recognising and appropriately treating 
this common condition (Table ii).44,45
5.  Recognition of disease (early 
diagnosis and staging of severity)
The diagnosis of cOpD should be considered in any patient with 
chronic progressive dyspnoea and/or chronic cough (with or without 
sputum production) with a smoking history of more than 10 pack-
years and/or other risk factors for cOpD.
correct diagnosis, and in particular the differentiation of cOpD 
from asthma, is important to ensure correct treatment. clinical 
features that assist in the diagnosis of each condition are outlined in 
Table iii. early detection of cOpD and effective smoking cessation 
interventions slow the decline in pulmonary function and may alter 
the natural history.
Table II. Goals of management of COPD
1. recognition of disease (early diagnosis and staging of 
severity)
2. prevention of disease progression (including smoking 
cessation)
3. alleviation of breathlessness and improvement in effort 
tolerance (treatment of airflow obstruction)
4. pulmonary rehabilitation and education (improving quality 
of life)
5. prevention and treatment of exacerbations
6. prevention and treatment of complications
7. reduction in mortality
Table III. Distinguishing features of COPD and asthma
features suggesting a diagnosis of COPD
•    Persistent unremitting dyspnoea, wheeze and productive cough 
despite treatment
•   A long history of smoking or exposure to other risk factors
•   Slow progression
•    Hyperinflation and abnormal spirometry that persist during a 
stable phase of the disease
•   Cyanosis
features that suggest the presence of asthma
•   Young age at onset
•   Presence of atopy and/or allergic rhinitis
•   Diurnal and day-to-day variation and seasonal variability
•    Marked improvement in lung function after a bronchodilator 
and/or a 2-week trial of systemic steroids
Additional considerations in the diagnosis of asthma and COPD
•    Asthma and COPD may co-exist, and distinguishing them may 
be difficult
•   Breathlessness occurs late in COPD
•    Asthmatics who smoke may have an accelerated decline in lung 
function
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clinical evaluation should include a history of exposure to tobacco 
smoking and other risk factors, an assessment of breathlessness (e.g. 
the Mrc dyspnoea scale (Table iv)), the occurrence and severity 
of exacerbations, and co-morbid conditions that could complicate 
management. physical examination may reveal signs of hyperinflation 
and airway obstruction but may be normal. co-morbid conditions 
should also be sought.
5.1  spirometry
spirometry is essential for the detection, assessment and management 
of patients with cOpD. it must be performed by adequately trained 
persons using a spirometer of approved standard and quality that is 
calibrated frequently. Measurements used in the diagnosis of cOpD 
are Fev1, Fvc and Fev1/Fvc% pre- and post-bronchodilator.
5.2  Detection of airflow obstruction
The presence of an Fev1/Fvc ratio of less than 70% confirms the 
presence of airflow obstruction. The Fev1 is usually reduced (less 
than 80% of predicted value), and is used as a measure of severity. 
Most patients with symptomatic cOpD have a reduced Fev1, but 
many patients with significantly reduced Fev1 have no symptoms.
5.3  Assessment of reversibility with short-
acting bronchodilators
spirometry should be performed before, and 20 minutes after, 4 puffs 
of a short-acting beta-2 agonist bronchodilator (e.g. salbutamol, 
fenoterol or terbutaline). an improvement in Fev1 ≥12% from 
baseline and ≥200 ml indicates significant reversibility. This is 
compatible with asthma but is also seen in many patients with cOpD. 
However, in general, the larger the improvement, the greater the 
likelihood that the diagnosis is asthma, especially with the clinical 
profile borne in mind (Table iii).
5.4  Assessment of severity of COPD
To establish the severity of airflow obstruction, Fev1 is expressed as 
a percentage of predicted values. The european community for steel 
and coal (ecsc) (based on surveys performed in europe)46 or the 
nHanes iii reference equations47 are recommended for routine use 
in south africa. ethnic differences (amounting to approximately 12% 
lower values for Fvc in africans or african-americans) have been 
demonstrated in some series, and a correction factor (multiplication of 
the spirometric value by 0.9) should be applied. Measurement of peak 
expiratory flow (peF), while helpful in asthma, is not an appropriate 
test for diagnosing and evaluating the severity of cOpD and does not 
distinguish obstructive from restrictive lung disease. The assessment 
of severity of cOpD is based on spirometric measures and clinical 
indicators including severity of dyspnoea, functional impairment and 
6-minute walking distance (6MwD).48 Grading of severity is used for 
prognostication and for selecting treatment. Details of the grades of 
severity are provided in Table v.
5.5  Monitoring disease progression
cOpD progresses slowly over years. More rapid deterioration suggests 
an acute exacerbation or alternative diagnosis e.g. asthma, cardiac 
failure and pneumothorax. progression of the disease could be 
monitored using the parameters in Table v, but serial measurement 
of Fev1 alone is probably most practical.
5.6  Chest radiography
a chest radiograph may show evidence of hyperinflation but frequently 
appears normal. it is also useful for detecting additional disease.
6.  Prevention of disease progression 
(including smoking cessation)
avoidance of occupational and environmental pollution, including 
passive or ‘side-stream’ tobacco smoke exposure is important, 
particularly in susceptible persons: pregnant women, infants and 
children, persons with alpha-1 protease inhibitor deficiency, and 
those with cOpD.
smoking cessation is the only measure that has been shown to 
slow the progression of cOpD, and is one of the most cost-effective 
interventions in health care.49 all smokers must be encouraged to 
stop smoking. Health care workers should be familiar with smoking 
cessation measures and promote these among their patients. 50  The 
advantages of cessation include: (i) slowing of the rate of decline of 
lung function (a small initial improvement in spirometry occurs in 
some), (ii) improved oxygen transport in blood, through reductions 
in carboxyhaemoglobin and blood viscosity, (iii) reduced tendency 
to thrombosis, (iv) improvements in appetite, body mass, muscle 
strength and exercise tolerance, (v) possible improved efficacy of 
some classes of drugs used in cOpD, and (vi) delayed development 
of respiratory failure and cor pulmonale.
6.1  smoking cessation programmes
There are many smoking cessation methods. Many are behavioural in 
approach, but some are pharmacological and involve gradual weaning 
from nicotine via nicotine replacement, with or without mood modifiers 
to counteract the negative effects of withdrawal. Many interventions 
show impressive short-term results, but long-term abstinence (defined 
as cessation without relapse for 12 months) occurs in <30% of patients 
Table Iv. Medical Research Council dyspnoea scale
Grade Description
1 not troubled by breathlessness except with strenuous 
exercise
2 Troubled by shortness of breath when hurrying on the 
level or walking up a slight hill
3 walks slower than people of the same age on the level 
because of breathlessness or has to stop  for breath when 
walking at own pace
4 stops for breath after walking about 100 m or after a few 
minutes on the level
5 Too breathless to leave the house or breathless when 
dressing or undressing
TABlE v. staging of COPD (fEv1/fvC <70%)
stage 1 
Mild
stage 2 
Moderate
stage 3 
severe*
stage 
4 very 
severe*
Fev1 after 
bronchodilator
≥80% 50 - 80% 30 - 50% <30%
Dyspnoea Mrc 2 Mrc 3 - 4 Mrc 5 Mrc 5
6MwD >600 m 200 - 600 m <200 m
*also severe if repeated hospitalisation for exacerbations and respiratory or right heart 
failure.
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(for most methods, only 15 - 20%). Factors associated with poor success 
include heavy smoking and relapse within the first 2 weeks.
6.2  features that contribute to a successful 
programme
6.2.1  at an initial in-depth interview, discuss the patient’s smoking 
habits and previous quit attempts. The 5 ‘a’s’ are an increasingly used 
memory aid for counseling smokers:
•   ‘ask’ do you smoke?
•   ‘advise’ to quit.
•   ‘assess’ the willingness to quit.
•    ‘assist’( aid) the patient to quit (provide counseling and 
medication).
•   ‘arrange’ follow-up contact.
6.2.2  cessation advised repeatedly by a doctor.
6.2.3.  abrupt cessation rather than gradual smoking reduction, with 
agreement on a quit date and provision of support for adherence to 
the commitment (by clinical visit or phone call). For recalcitrant 
smokers, reduction is possible and enhances subsequent cessation.
6.2.4.  reinforcement and follow-up.
6.2.5.  There are three medications for smoking cessation: (i) nicotine 
replacement therapy (nrT) with 4 approved formulations: gum, patch, 
sublingual tablets and an oral spray, (ii) Bupropion, an antidepressant 
and (iii) varenicline, a newly developed partial nicotine agonist. 
These medications are mostly used as single treatments but, for more 
dependent smokers, combinations of more than 1 nrT or nrT with 
Bupropion have been shown to be effective.
7.  Alleviation of breathlessness and 
improvement in effort tolerance 
(treatment of airflow obstruction)
7.1  Bronchodilators
Bronchodilators form the mainstay of the treatment of cOpD, for 
which inhaled beta-2 agonists, inhaled anticholinergics and oral 
theophyllines are all effective. individuals vary in their responsiveness 
to each, and combinations may have additive effects.51-53 commence 
treatment in symptomatic patients with an inhaled short-acting 
bronchodilator on a prn basis. Thereafter, increase treatment 
stepwise to include inhaled long-acting bronchodilators, slow-
release theophylline and inhaled corticosteroids (ics) in various 
combinations (see Fig. 1).
7.1.1  Inhaled short-acting beta-2 agonists
These agents have a rapid onset of action. examples include 
salbutamol, fenoterol and terbutaline.
7.1.2  Inhaled long-acting beta-2 agonists
The long-acting beta-2 agonists (laBa) are salmeterol and formoterol. 
laBas are more effective and more convenient than regular short-
acting beta-2 agonists. Their use as monotherapy (without inhaled 
corticosteroids) appears to be safe (in contrast to asthma). laBas 
improve symptoms, reduce exacerbations, reduce rescue therapy 
requirements and improve exercise capacity (evidence a).54 regular 
use does not result in loss of efficacy. Formoterol may also be used as 
reliever treatment because of its rapid onset of action.
7.1.3  Combination of lABA and ICs
a combination of laBa + ics therapy:
•    reduces the number of acute exacerbations in patients with 
moderate to severe cOpD (evidence a)
•    improves Fev1 (evidence B)
•    improves health-related quality of life (evidence B)
•    may increase the risk of pneumonia (evidence B).55,56
7.1.4  Inhaled anti-cholinergics
anticholinergic agents are effective bronchodilators for cOpD 
because the disease is associated with increased vagally mediated 
bronchoconstriction. ipratropium bromide is a short-acting agent 
with a peak bronchodilator effect at approximately 40 minutes and 
between 4 - 6 hours duration of action. Tiotropium bromide is a long-
acting anticholinergic with a slow onset of peak bronchodilation but 
a 24-hour duration of action facilitating once-daily administration. 
They are more effective than beta-2 agonists in many patients 
and have fewer side-effects (dry mouth and urinary retention). 
ipratropium bromide is prescribed for as-needed use for symptom 
relief in cOpD and can also be used 4 - 6-hourly as a maintenance 
bronchodilator agent. Tiotropium may be used as a first-line long-
acting bronchodilator treatment in cOpD or may be used in 
combination with laBas because of their different mechanisms of 
action. Tiotropium has been shown to improve quality of life and 
reduce exacerbation rates and hospitalisation (evidence a).57-60 it is 
available as a dry powder inhaler and requires an inspiratory flow rate 
of at least 30 l/min for optimal respiratory tract delivery.
7.1.5  Nebuliser treatment
This is an alternative for stage 3 and 4 patients with poor inhalation 
technique and/or acute dyspnoea.
•    nebulised ipratropium plus beta-2 agonist can be used up to 3 or 
more times daily.61,62while there are distinct advantages, nebulisers 
tend to be overused.
•    patients requiring chronic nebuliser therapy should, where 
possible, have specialist assessment.
7.1.6  Theophyllines
Theophyllines have similar bronchodilator effects to beta-2 agonists. 
They improve quality of life, and the oral route of administration is an 
advantage for some patients.63 limitations include toxicity (particularly 
in the elderly), drug interactions and variable metabolism. The 
recommended dose of oral slow-release theophylline is 200 - 400 mg 
twice a day or 400 - 800 mg at night, and should not be exceeded without 
monitoring blood levels. combination tablets containing theophylline 
and other bronchodilators or sedatives are not recommended.
7.1.7  Combination bronchodilator treatment
a combination of bronchodilator agents is recommended and has 
additive effects. The following combinations are effective:64,65
•    saBa + ipratropium
•    long-acting anti-cholinergic + saBa
•    long-acting anti-cholinergic + laBa
•    laBa + ipratropium.
Oral theophylline may be added to any combination of inhaled 
treatment.
7.2  Inhaled corticosteroids
inhaled corticosteroids, particularly in combination with laBas, 
have been shown to improve lung function, quality of life and reduce 
GuIDElINEs
Fig. 1. Therapy at each stage of COPD
January 2011, vol. 101, no. 1  sAMJ68
exacerbations.55,56 The best evidence for their efficacy is in patients 
with ≥3 exacerbations per year, especially in severe disease. patients 
need to be carefully monitored for side-effects such as skin bruising 
and oral candidiasis.
7.3  Oral corticosteroids
Oral corticosteroids are no longer recommended for stable cOpD.66 
low-dose oral corticosteroids only cause small improvements in lung 
function. Higher doses (≥30 mg/d) are associated with improvements 
in lung function but also with major side-effects that include 
aggravation of blood pressure, hyperglycaemia, decreased adrenal 
function and osteoporosis. an oral corticosteroid trial is no longer 
utilised to determine corticosteroid-responsive subjects as such a 
phenotype cannot be distinguished.67 it is only recommended in 
instances where the clinical profile makes distinction between asthma 
and cOpD difficult. a marked improvement in spirometry and 
symptoms following a corticosteroid trial would suggest asthma.
7.4  Newer phosphodiesterase inhibitors
phosphodiesterase inhibitors, such as roflumilast, have been shown 
to be effective in phase iii clinical trials but are not yet registered for 
use in south africa.
7.5  Mucolytics and mucokinetic agents
expectoration of tenacious sputum is a distressing symptom. 
unfortunately, mucolytics, mucokinetic drugs, cough syrups and 
acetylcysteine (oral and inhaled) have not been shown to be effective, 
and are not recommended.
7.6  Chest physiotherapy
an ineffective cough may be improved by instruction in the ‘huff 
technique’ of coughing and active cycle of breathing. percussion and 
vibration therapy do not form part of routine management in stable 
patients. The physiotherapist has an important role in directing the 
conditioning (exercise) programme and in advising on breathing and 
coughing techniques.
7.7  venesection
an increased haematocrit causes aggravation of cardiac failure, 
increased ventilation/perfusion abnormality and an increased 
incidence of thrombotic episodes. when the haematocrit is >0.55, 
therapeutic venesection should be considered; this can be repeated to 
maintain the haematocrit in the normal range.
7.8  Assessment of response to therapy
The Fev1 is useful as a diagnostic and prognostic tool and is also 
of value in monitoring disease progression. it is not as useful for 
assessing response to treatment. Other lung function measurements 
to monitor response include inspiratory capacity (ic), residual 
volume (rv) and functional residual capacity (Frc).68 The response 
to treatment can also be gauged by the improvement in dyspnoea, 
and the Mrc dyspnoea scale (Table iv) is used to quantify the degree 
of dyspnoea. The 6-minute walking distance test can be used to assess 
response to therapy as well. (appendix B).
8.  Pulmonary rehabilitation and 
education (improving quality of life)
rehabilitation is a team effort involving the doctor, physiotherapist 
and/or biokineticist. conditions such as uncontrolled hypertension, 
and overt or silent cardiac ischaemia, have to be treated before 
inclusion in a programme.69-74 Details of a rehabilitation programme 
are described in appendix D. rehabilitation can be undertaken 
in resource-limited settings using supervised walking as a major 
component.
9.  Prevention and treatment of acute 
exacerbations of COPD
9.1  Definition, natural history and diagnosis 
of exacerbations
an exacerbation is defined as an increase in symptoms of cOpD 
above the usual day-to-day variation experienced by the patient, 
and necessitating a change in treatment. exacerbations vary in both 
severity and frequency. They tend to become more common as 
cOpD progresses. exacerbations severely affect quality of life, may be 
associated with permanent worsening of cOpD, account for a large 
percentage of the direct costs associated with the treatment of cOpD, 
and increase mortality. The most common cause of exacerbations is 
tracheobronchial infections.
acute exacerbations must be distinguished from other diseases 
and complications of cOpD (including pneumonia, pneumothorax, 
congestive heart failure, arrhythmias and pulmonary embolism) that 
require alternative treatment. when exacerbations are associated with 
features of infection (pyrexia and purulent sputum), the presence of 
pneumonia and other forms of lower respiratory infection should 
be excluded using a chest radiograph. an approach to the antibiotic 
treatment of acute exacerbations of cOpD is provided below (par. 
9.3.3) and in appendix c.
9.2  Prevention of exacerbations
The following measures have been shown to reduce the frequency 
and/or severity of cOpD exacerbations (evidence a):49,55-57,64,65,73
•    smoking cessation
•    prevention of respiratory infections (influenza and pneumococcal 
vaccination)
•    bronchodilator treatment
•    inhaled corticosteroids.
9.3  Management of exacerbations1,2,41,45
9.3.1  Bronchodilators
•    nebulisations with short-acting bronchodilators may be given 
4-hourly (or as often as every 30 - 60 minutes or continuously in 
severe cases). Multiple actuations of an MDi delivered via a large 
(>500 ml) spacer device may be as effective as nebulisation.
•    should there be an inadequately sustained response to the above 
treatment, oral or intravenous theophyllines may be used.
9.3.2  Corticosteroids
corticosteroids should preferably be given orally (evidence a). a 
once-daily dose of 30 - 40 mg prednisone is recommended to be 
continued for 7 - 10 days (evidence c). Tapering is not required. an 
equivalent dose of an intravenous steroid may be given if the patient 
is unable to take oral medication.
9.3.3  Antibiotics (see Appendix C)
These should be prescribed when there is evidence of a severe 
exacerbation (as evidenced by the 3 cardinal symptoms of increased 
sputum volume, sputum purulence and increased dyspnoea) or 
in those who require ventilation (evidence B). if the patient has 
2 of the cardinal symptoms, of which one is increased sputum 
purulence, they should also receive antibiotics (evidence c). sputum 
Gram-stain may be of help by confirming the presence of relevant 
organisms, but is not an essential investigation. The organisms most 
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commonly involved are Streptococcus pneumoniae, Haemophilus 
influenzae and Moraxella catarrhalis. with the increasing appearance 
of penicillin- and macrolide-resistant pneumococci, and beta-
lactamase-mediated resistance of H. influenzae and M. catarrhalis, 
local sensitivity data should be considered when choosing an 
antibiotic. Macrolides should be avoided in areas where there are 
high levels of resistance. alternatives are amoxicillin/clavulanate, 
cefuroxime, or fluoroquinolones. The oral route of administration is 
preferred except for severe illness. The duration of treatment should 
be 5 - 7 days (evidence a).
9.3.4  Oxygen therapy
Oxygen should be started at 24% or 1 - 2 l/minute by nasal cannula. 
increases should be gradual to avoid carbon dioxide narcosis. 
This should be guided by blood gas analysis or by the level of 
consciousness if blood gases are not available. The aim should be to 
maintain the saturation above 90%.
9.3.5  Physiotherapy to assist with clearance of 
secretions. 
postural drainage and chest percussion are of limited benefit and can 
aggravate fatigue and respiratory failure.
9.3.6  Indications for hospitalisation
•    severe cOpD
•    any of the following features:
•    sustained failure to improve on outpatient management 
•    inability to walk between rooms (where previously mobile)
•    family and/or physician unable to manage the patient at home
•    high-risk co-morbid condition, whether pulmonary (e.g. 
pneumonia) or non-pulmonary
•    prolonged progressive worsening of symptoms before emergency 
visit
•    altered mentation
•    worsening hypoxaemia and new or worsening hypercapnia
•    new onset arrhythmia
•    elderly or frail patient
•    new or worsening right-sided cardiac failure unresponsive to 
outpatient management.
9.3.7  Indications for ICu admission
pre-conditions for icu admission:
•    satisfactory functional status before the exacerbation (patient 
coped with activities of daily living); if not known, the patient 
should be given the benefit of the doubt
•    possible need for mechanical ventilation i.e. paO2 <6.7 kpa (50 
mmHg) on room air, arterial blood pH <7.3, and confusion
•    the presence of a reversible factor. examples are infections, 
bronchospasm, oxygen-induced carbon dioxide narcosis, 
sedative administration, heart failure or other associated 
illnesses.
9.3.8  ventilatory support must be considered for the patient 
with one or more of the following features:
•    exhaustion, confusion, coma
•    pH <7.3 and declining (respiratory acidosis)
•    respiratory or cardiac arrest
•    inability to clear secretions.
 Modalities of ventilatory support include invasive (mechanical 
ventilation) and non-invasive continuous positive airways pressure 
(cpap) or Bipap techniques. patients considered suitable for non-
invasive ventilation are those who are able to protect their airway and 
clear their airway secretions. indications for non-invasive ventilation 
(niv) include the following (all criteria should be met):
respiratory rate >30 breaths/minute
•    pH <7.35
•    pcO2 >6.7 kpa (>50 mmHg)
•    paO2 <6.7 kpa (<50 mmHg) on room air.
 contra-indications to non-invasive ventilation include haemodynamic 
instability, decreased level of consciousness or poor co-operation, 
vomiting and excessive secretions. appearance of any of these features 
in a patient undergoing niv who still needs ventilation would be an 
indication for intubation and mechanical ventilation.
non-invasive positive pressure ventilation in acute exacerbations 
has been shown to improve blood gases and pH, reduce in-hospital 
mortality, decrease the need for invasive mechanical ventilation, and 
decrease the length of hospital stay (evidence a).
10.  Prevention and treatment of 
complications
The main complications include right heart failure, severe 
exacerbations, pulmonary embolism, pneumothoraces, erythrocytosis 
and chronic respiratory failure.
10.1  The management of right heart failure
•    identify and treat the precipitating cause. in cOpD, this 
might include an acute respiratory infection, worsening airflow 
obstruction (review bronchodilator and other treatment) or 
worsening hypoxaemia from additional factors such as a move to 
higher altitude or a thrombo-embolic event.
•    correction of hypoxaemia with long-term oxygen as indicated 
under long-term oxygen therapy (lTOT), see paragraph 6.3) 
(evidence D).
•    Diuretics (e.g. hydrochlorothiazide 25 mg or equivalent). avoid 
large decreases in preload which may precipitate hypotension and 
renal impairment.
•    Digoxin must be avoided except in the presence of atrial fibrillation 
and/or left ventricular dysfunction/failure (evidence c).
•    ace inhibitors and calcium antagonists are not indicated for 
the management of cor pulmonale or right ventricular failure 
(evidence B).
•    prophylaxis with subcutaneous heparin to prevent deep vein 
thrombosis during periods of exacerbation or prolonged 
immobilisation (evidence a).
•    chronic treatment with warfarin needs to be considered in cOpD 
patients with atrial fibrillation or thrombo-embolic complications 
(evidence a). There is no evidence of benefit when used routinely 
in patients with cor pulmonale secondary to cOpD (evidence c).
10.2  Pneumothorax
The development of a spontaneous pneumothorax must be considered 
when patients with stable cOpD suddenly deteriorate, as patients 
with respiratory impairment tolerate even a small pneumothorax 
poorly.
10.3  long-term oxygen therapy (lTOT)
The full benefit is only evident in patients with persistent hypoxaemia 
(with or without hypercapnia) in the stable phase of cOpD. in such 
patients, it has been shown to reduce the complications of respiratory 
and right heart failure and to improve survival.
10.3.1  Indications for lTOT
•    stable, severe cOpD (usually but not exclusively with an Fev1 
<1.5 l and Fev1/Fvc <70%) on optimal bronchodilator therapy. 
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The decision to prescribe lTOT should only be made once the 
patient has fully recovered from an acute exacerbation ( usually 
after 6 weeks).
•    arterial hypoxaemia (paO2 <7.3 kpa or 55 mmHg at sea-level) 
or oxygen saturation <90% at rest.
•    smoking cessation for ≥3 months.
Hypoxaemia must be confirmed by arterial blood gases performed 
while the patient is breathing  room air. Following exacerbations of 
cOpD, spirometry and paO2 may continue to improve for up to 3 
months. Therefore, these should ideally be checked in all patients 
on 2 occasions at least 1 month, and preferably 3 months, apart 
before prescribing lTOT. continued smoking reduces the efficacy of 
treatment and is a contra-indication to oxygen therapy. worsening 
hypercapnia caused by hypoventilation is an occasional complication 
of oxygen therapy in patients with severe cOpD and hypercapnic 
respiratory failure. regular follow-up by a suitably experienced 
physician and ready access to technical advice, either through a 
private contractor or a hospital department, must be available. 
assessment of adherence is essential.
10.3.2  Oxygen prescription
Oxygen is administered by facemask or nasal cannula for a total 
of at least 16 hours per 24-hour day. a flow rate of 1 - 2 l/minute 
is used, the rate being determined in each case by arterial blood 
gas determinations. Oximetry may be used for follow-up checks. 
Oxygen can be delivered by oxygen concentrators or by cylinders. 
concentrators are more convenient and cost effective. portable 
oxygen systems include bottled oxygen with flow-saving devices and 
portable concentrators. with these systems, patients do not have to 
be confined to home.
10.4  Palliative symptomatic oxygen therapy
Oxygen given for short periods to relieve breathlessness in hypoxic 
patients with cOpD does not influence the natural progression of 
the disease and is therefore not routinely recommended. patients in 
whom a fall in paO2 occurs during exercise may improve their exercise 
capacity with supplemental oxygen. patients who desaturate at night 
should be assessed for sleep apnoea and treated appropriately.
10.5  Additional considerations
10.5.1. sleep in COPD
sleep is associated with a decrease in arterial oxygen saturation 
(saO2) in most individuals that is more marked in cOpD. significant 
night-time hypoxaemia cannot be predicted from measurement of 
daytime blood gas and pulmonary function tests, but if the daytime 
paO2 is ≥8 kpa, nocturnal saO2 need only be measured if unexplained 
respiratory failure, cor pulmonale or erythrocytosis are found. 
referral for a full sleep study (polysomnography) and a specialised 
opinion should only be considered if sleep-disordered breathing 
is suspected (i.e. daytime hyper-somnolence and other symptoms 
of sleep deprivation, or a strong history of loud snoring with 
apnoeic events). long-term oxygen therapy, prescribed for daytime 
hypoxaemia, must be used during sleep.
10.5.2. surgery for COPD
surgical techniques that can improve lung function and symptoms 
of cOpD include:
•    bullectomy
•    lung volume reduction surgery
•    lung transplantation.
Bullectomy
This may be indicated to decompress adjacent lung parenchyma if there 
are large localised bullae. This can  be performed thoracoscopically, 
and may reduce dyspnoea and improve lung function (evidence c).
lung volume reduction surgery (lvRs)
in this procedure, parts of the lung are resected to reduce 
hyperinflation. it is an alternative to lung transplantation in patients 
with severe inhomogeneous emphysema who remain symptomatic 
despite optimal medical therapy. The Fev1 improves by about 10% 
with larger improvements in exercise tolerance, dyspnoea and quality 
of life.
The ideal candidate should be carefully selected by a multi-
disciplinary team including the general practitioner, pulmonologist 
and thoracic surgeon. Guidelines include a Fev1 20 - 35% of 
that predicted, diffusion capacity for carbon monoxide >20% 
predicted, hyperinflation with inhomogeneous disease and limited 
co-morbidities. in experienced units, survival after 4 years is 54% 
v. 39.7% for medical therapy in patients with mainly upper lobe 
emphysema and low exercise capacity. lvrs remains an expensive 
palliative surgical procedure and is recommended only in carefully 
selected patients. new techniques to effect lvr using valves or 
biological substances are being investigated.
lung transplantation
This approach may be used in patients with diffuse severe emphysema, 
but access to transplantation is severely limited in south africa. 
its effect on survival after 2 years remains controversial. General 
guidelines recommend that the patient must be <65 years old 
without any other medical condition that could shorten predicted 
survival. additional criteria for referral include Fev1 <35% predicted, 
paO2 <7.3 - 8.0 kpa, pacO2 >6.7 kpa and secondary pulmonary 
hypertension.
10.5.3  surgery in COPD
post-operative pulmonary complications constitute a significant 
cause of morbidity and mortality. The frequency varies from 2 - 
70%. The complications are atelectasis, infection (bronchitis and 
pneumonia), respiratory failure necessitating prolonged mechanical 
ventilation, exacerbation of cOpD, bronchospasm and pulmonary 
embolism. stratification of risk for pulmonary complications entails 
patient-related as well as procedure-related risk factors. preoperative 
evaluation depends strongly on taking a thorough history and 
clinical examination. it is reasonable to perform a preoperative chest 
radiograph in patients with cardiopulmonary disease and those 
>50 years undergoing high-risk surgery. pre-operative preparation, 
optimisation of airway function (bronchodilators, steroids, antibiotics 
and chest physiotherapy), smoking cessation, weight reduction where 
applicable, delay of elective surgery if chest infection is present, 
and patient education on deep breathing exercises, coughing, pain 
control and incentive spirometry are recommended. post-operative 
measures include early mobilisation and ambulation, prophylactic 
lung expansion manoeuvres, adequate analgesia and prophylaxis 
against thrombosis.
10.5.4  spacer devices and delivery methods
The use of spacer devices may improve delivery of medication to the 
lower airways in patients with poor inhaler technique and poor lung 
function. some patients may achieve better results with dry powder 
devices. it is vital to ensure that the individual uses the inhaler device 
correctly.
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10.5.5  Air travel
cOpD patients who travel by commercial aircraft put themselves at 
risk for a range of complications. respiratory incidents comprise 9 - 
10% of airborne emergencies. Therefore the need to travel needs to 
be balanced against the potential risks. potential travelers with cOpD 
should have stable disease (no recent exacerbations, hospitalisations 
or acute illnesses). co-morbid disease increases the risks of in-flight 
emergencies i.e. ischaemic heart disease, congestive cardiac failure 
and cor pulmonale (56% of all in-flight emergencies). potential 
problems include:
•    hypoxaemia at altitude: stable cOpD patients with an oxygen 
saturation (saO2) of 95% preflight desaturate to about 86% at a 
cabin altitude of 2 165 m. This worsens to 78% with activity.
•    worsening of existing hypoxia at ground level
•    pulmonary hypertension
•    worsening discomfort and dyspnoea at altitude
•    cardiac dysrhythmias
•    risk of contracting a respiratory infection
•    pneumothorax from large bullae.
The most practical evaluation includes room air saO2 measurements 
pre-flight. if the saO2 is less than 92%, further assessment is necessary. 
available tests are :
•    50 m walk test. Those who desaturate will require supplemental 
O2.
•    hypoxic inhalation test. patients breathe 15% FiO2 at sea level. 
Those with significant desaturation will need supplemental O2.
•    hypobaric chamber simulating in-flight conditions .Their limited 
availability precludes widespread use in assessing patients.
 The in-flight requirement would be 2 l/min higher than home use, 
or 2 - 4 l/minute if the assessment indicates the need for O2.
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Appendix A
Process of guideline revision
in 2008, the council of the south african Thoracic society resolved 
to revise the 2004 cOpD guideline and appointed a convenor ( 
Dr abdool-Gaffar) and editorial committee, selected a review date 
and agreed on the process of revision. Membership of the working 
Group comprised most members of the previous working group 
and general practitioners. The editorial committee identified areas 
of the guideline that required revision and commissioned members 
of the working group to prepare reviews of new data in these areas, 
with particular reference to the content of the latest version of the 
Global Obstructive lung Disease Guideline. The workshop was held 
in august 2008. a draft revision document, based on the consensus 
obtained at the workshop, was compiled by the editorial board, and 
circulated to the guideline committee for further comment in 2009. 
These comments were considered by the editorial committee, and the 
final draft was then completed and approved by the council of the 
south african Thoracic society by postal vote in May 2010.
Appendix B
The 6-minute walk test (6MWT)75
The 6MwT is a composite and repeatable test of lung, heart and 
muscle function. Measurement of specific exercise-induced outcomes 
are an extremely important adjunct to clinical and lung function 
evaluation. The 6MwT does not correlate well with Fev1 but 
relates to the degree of exercise-induced hyperinflation of cOpD 
patients, and is used extensively as a prognostic indicator for patients 
with cOpD, interstitial lung disease or pulmonary hypertension. 
it provides better insight into the degree of exercise impairment 
compared with single evaluations such as spirometry or an ecG.
The 6MwT has to be conducted under supervision of a trained 
medical or paramedical person who can recognise untoward exercise-
induced symptoms. prior to the test, patients have to be evaluated 
to rule out uncontrolled hypertension, ischaemic heart disease, 
arrhythmias and heart failure that may complicate the assessment 
or endanger the patient. These conditions need adequate treatment 
before the 6MwT can be conducted. patients with lower limb 
arthritis or claudication and those who are mentally challenged or old 
and infirm will not perform the test adequately. it can be conducted 
in any facility that has the necessary resuscitation equipment and 
a straight, flat surface of 30 meters or a treadmill. prior to the test, 
patients need to be counseled to motivate them to achieve the greatest 
distance. They also need to be informed that they may rest during 
the test but that it will be recorded as part of their 6MwT walk 
time. all cOpD patients need to use their bronchodilators before 
attempting the 6MwT, and they should not be exercised during an 
infective episode or if they are in the immediate recovery phase of an 
exacerbation.
a baseline ecG is done and should be repeated after the first effort 
to record any asymptomatic exercise-induced ischaemic changes. 
The oxygen saturation of blood should be measured before and 
after the test. Determination of pulse rate, blood pressure and 
respiratory rate along with the blood oxygen saturation level should 
be recorded before and after the test. a level in the latter <90% or 
a decline >5% will identify those patients who will require oxygen 
during the test. patients’ opinions as to their degree of exhaustion 
need to be recorded on a Borg scale card (Fig. 2) which provides a 
semi-quantitative estimation of fatigue and dyspnoea. recovery time 
should be noted by measuring the respiratory and heart rates at 3 
and 5 minutes after the test. repeatability of the 6MwD (distance) 
of 10% should be achieved. in this respect, a second or, if required, 
even a third 6MwT should be conducted after periods of rest of up 
to 20 minutes. The 6MwT should be discontinued in patients who 
complain of chest pain, intolerable dyspnoea or leg cramps, or appear 
to be staggering or have an ashen or pale appearance. a mean value 
for males of 464 metres and 430 metres for females is the standard for 
a healthy american population. a post-intervention improvement of 
54 meters above the baseline 6MwD has been found to represent a 
clinically meaningful improvement in cOpD patients who undergo 
rehabilitation.
Fig. 2. 10-point Borg Category Scale of dyspnoea and fatigue 
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7 Very severe 
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10 Maximal 
 
 Fig. 2. 10-point Borg Category Scale of dyspnoea and fatigue
63.    ram,Fs, Jones, pw, castro, aa, et al. Oral theophylline for chronic obstructive pulmonary disease. 
cochrane Database syst rev 2002; cD003902.
64.    aaron sD, vandemheen kl, Ferguson D, et al. Tiotropium in combination with placebo, salmeterol, 
or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. 
ann intern Med 2007;146:545.
65.    Tashkin Dp, celli B, senn s, et al. a 4-year trial of tiotropium in chronic obstructive pulmonary disease. 
n engl J Med. 2008;359:1543-1554.
66.    walters Jae, walter eH, wood-Baker r. Oral corticosteroids for stable cOpD. cochrane Database of 
systematic reviews 2005. cD 005374.
67.    Burge s, calverly pMa, Jones pw, spencer s, anderson Ja. prednisolone response in patients with 
cOpD: results from isOlDe. Thorax 2003;58:654-658.
68.    Marin JM, carrizo sJ, Gascon M, sanchez a, Gallego B, celli Br. inspiratory capacity, dynamic 
hyperinflation, breathlessness and exercise performance during the 6-minute-walk test in chronic 
obstructive pulmonary disease am J resp. crit care Med 2001;163:1395-1399.
69.    Mohsenifar Z, lee sM, Diaz p, et al. single-breath diffusing capacity of the lung for carbon monoxide. 
a predictor of paO2, maximum work rate and walking distance in patients with emphysema chest 
2003;123:1394-1400.
70.    De klerk D. an adapted rehabilitation program for a cross section of south african chronic obstructive 
pulmonary disease patients. phD thesis,Faculty of sport science, stellenbosch university, 2008.
71.    casaburi r, kukafka D, cooper cB, witek TJ Jr, kesten s. improvement of exercise tolerance with 
the combination of tiotropium and pulmonary rehabilitation in patients with cOpD. chest 2005;127: 
809-817.
72.    peters MM, webb ka, O’Donnell De. combined physiological effects of bronchodilators and hyperoxia 
on exertional dyspnoea in normoxic cOpD. Thorax 2006;61:559-567.
73.    Garcia-aymerich, lange p, Benet M, schinohr p, antó iM. regular physical activity reduces hospital 
admissions and mortality in chronic obstructive pulmonary disease: a population based cohort study. 
Thorax 2006;61:772-778.
74.    Morgan MD. preventing hospital admissions for cOpD: role of physical activity. Thorax 2003;58:95-
96.
75.    aTs statement. Guidelines for the six-minute walk test am J resp crit care Med 2002;166:111-117.
Accepted 14 September 2010.
GuIDElINEs
73January 2011, vol. 101, no. 1  sAMJ
Diagnosis Criteria/risk factors usual pathogens Recommended treatment*
1.   simple chronic  bronchitis •   Younger patient
•   FEV1 >60% predicted
•   Recent increase in sputum 
volume and purulence
•  H. influenzae
•  M. catarrhalis
•  S. pneumoniae acid
•   Beta-lactam resistance 
possible
•  Aminopenicillin
•  Amoxycillin-clavulanic
•  Macrolide/azalide/Ketolide
2.   complicated chronic 
bronchitis
•  Older age
•  FEV1 < 60% predicted
•  >4 exacerbations/year
•   Recent increase in sputum 
volume and purulence
•   Same organisms as in 1, but 
beta-lactam resistance more 
common
•   Sputum Gram stain and 
culture advised
•  Amoxycillin-clavulanic acid
•   Second or third generation 
cephalosporin
•  Respiratory fluoroquinolone
3.   complicated chronic 
bronchitis with chronic 
bronchial sepsis.
•   As above with purulent sputum 
for long periods in year
•   X-ray evidence of structural 
lung disease
•   Same as 2, but also 
enterobacteriaciae and 
Pseudomonas aeruginosa
•   Sputum Gram stain and 
culture advised
•  Ciprofloxacin or
•  Respiratory fluoroquinolone
•   Alternative based on result of 
sputum culture
* selection of antibiotic is influenced by knowledge of antibiotic resistance patterns in different areas of the country.
**adapted from Grossman rF. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations  of cOpD. chest 1998;113:249-255.
Appendix C
Antibiotic use in exacerbations of COPD
chronic bronchitis, with attendant mucociliary dysfunction and 
mucus hypersecretion, is the major pathological component that is 
responsible for the risk of bacterial colonisation and acute infective 
exacerbations of cOpD.
Recommendations for the antibiotic management of 
acute exacerbations of COPD based on a classification 
of bronchitis
Appendix D
Pulmonary rehabilitation
rehabilitation is a team effort in which the doctor, a physiotherapist or 
biokineticist motivate patients to achieve an exercise-orientated lifestyle. 
all cOpD patients who are dyspnoeic, regardless of their measured Fev1, 
qualify for the rehabilitation process. Factors such as exercise-induced 
hypoxia and exercise-induced hyperinflation in subsets of cOpD patients 
aggravate the muscle weakness and enhance the level of dyspnoea.
a thorough pre-rehabilitation evaluation needs to be done by an 
appropriately experienced doctor. Three aspects should be considered:
•    The first is to identify individuals who should be temporarily precluded 
from the rehabilitation programme. conditions such as uncontrolled 
hypertension and overt or silent cardiac ischaemia that may cause 
heart failure have to be treated before inclusion. additionally, those 
who have acute lower respiratory tract infections or arrhythmias will 
first require treatment for their immediate illness.
•    Secondly, the evaluation should include a baseline measurement of 
cardiac and lung function such as spirometry, dyspnoea assessment as 
well as a baseline 6MwT. These measurements will serve as points of 
reference for comparison during and after the rehabilitation process.
•    A third important aspect of the evaluation is explaining the 
rehabilitation process, emphasising the goals that need to be 
achieved and general motivation to achieve the best outcome.
rehabilitation improves exercise capacity, reduces perceived 
dyspnoea during exertion, enhances the health-related quality of 
life and reduces the number of hospitalisations and days in hospital. 
patients should be prepared for at least 25 rehabilitation sessions of 
one hour each under the guidance of a trained staff member. The 
sessions should be conducted at a tempo of 2 - 3 per week. Goal-
setting and motivation should be maintained throughout to retain the 
advantages achieved during the programme. The programme should 
include balanced endurance and muscle strengthening exercises 
with emphasis on the thigh, shoulder and respiratory muscles. The 
rehabilitation process complements and enhances quality of life, 
dyspnoea improvement and exercise tolerance to a greater extent than 
pharmacological treatment alone. patients who initially desaturate 
during the pre-rehabilitation evaluation should not be excluded. if 
their O2 saturation drops below 90%, the rehabilitation programme 
should be conducted with the patient on oxygen.
in a south african study,70 individuals who underwent 
rehabilitation predominantly in the open air under professional 
supervision improved their 6MwT, quality of life estimation and 
degree of dyspnoea to the same extent as a group of patients who had 
been rehabilitated in a fully equipped gymnasium. The importance of 
maintaining a long-term exercise programme for cOpD patients to 
lower their risk for hospital admission and death has been established. 
in this context, the post-rehabilitation evaluation conducted by 
the referring physician, during which the 6MwT and dyspnoea 
calculation is repeated and compared with the pre-rehabilitation 
values, can be extremely rewarding for patients. regular enquiry and 
motivation by the doctor during the long-term follow-up is required 
to keep patients from slipping back into an inactive lifestyle.
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